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In the past decade much has been learned about how Cystic FibrosisTransmembrane Con-
ductance Regulator (CFTR) folds and misfolds as the etiologic cause of cystic fibrosis (CF).
CFTR folding is complex and hierarchical, takes place in multiple cellular compartments and
physical environments, and involves several large networks of folding machineries. Inser-
tion of transmembrane (TM) segments into the endoplasmic reticulum (ER) membrane
and tertiary folding of cytosolic domains begin cotranslationally as the nascent polypeptide
emerges from the ribosome, whereas posttranslational folding establishes critical domain–
domain contacts needed to form a physiologically stable structure. Within the membrane,
N- and C-terminal TM helices are sorted into bundles that project from the cytosol to form
docking sites for nucleotide binding domains, NBD1 and NBD2, which in turn form a sand-
wich dimer for ATP binding. While tertiary folding is required for domain assembly, proper
domain assembly also reciprocally affects folding of individual domains analogous to a
jig-saw puzzle wherein the structure of each interlocking piece influences its neighbors.
Superimposed on this process is an elaborate proteostatic network of cellular chaperones
and folding machineries that facilitate the timing and coordination of specific folding steps
in and across the ER membrane. While the details of this process require further refine-
ment, we finally have a useful framework to understand key folding defect(s) caused by
∆F508 that provides a molecular target(s) for the next generation of CFTR small molecule
correctors aimed at the specific defect present in the majority of CF patients.
Keywords: cystic fibrosis, CFTR, membrane protein biogenesis, protein translocation, cotranslational folding,
nucleotide binding domain, ABC transporter
INTRODUCTION
Cystic fibrosis (CF) is one of a growing number of human diseases
caused by inherited mutations that disrupt protein folding. It is
caused by dysfunction of the Cystic Fibrosis Transmembrane con-
ductance Regulator (CFTR), a cAMP-regulated ion channel that
resides in the apical membrane of epithelial cells (Riordan, 2008;
Lubamba et al., 2012). CFTR dysfunction can occur by defects
in protein synthesis, folding, intracellular trafficking, channel gat-
ing, chloride conductance, or plasma membrane stability. In each
case, loss of CFTR results in abnormalities of water, chloride,
and/or bicarbonate transport that lead to dysfunction of target tis-
sues including: pancreatic insufficiency, increased sweat chloride,
intestinal obstruction, and most importantly, chronic pulmonary
infection, inflammation, and ultimately death due to respiratory
failure (Cohen and Prince, 2012; Ratjen and McColley, 2012). The
most prevalent CFTR mutation, Phe508del (∆F508), is found in
∼90% of CF patients (Riordan et al., 1989) where it impairs CFTR
folding, inhibits channel gating, and decreases plasma membrane
stability (Lukacs and Verkman, 2012). The mechanisms by which
∆F508 disrupts CFTR folding are beginning to be understood, and
small molecule modulators that restore endoplasmic reticulum
Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conduc-
tance regulator; ER, endoplasmic reticulum; NBD, nucleotide binding domain; PCC,
protein conducting channel; RNC, ribosome nascent chain complex; RTC, ribosome
translocon complex; TM, transmembrane segment.
(ER) trafficking and channel gating hold great promise for new
treatments to correct these underlying molecular abnormalities in
CF patients.
Cystic fibrosis transmembrane conductance regulator is a 1480
amino acid polytopic glycoprotein in the ABC transporter family
(ABCC7) that contains two six-spanning transmembrane (TM)
domains (TMD1 and TMD2) that form the channel pore, two
cytosolic nucleotide binding domains (NBD1 and NBD2) that
drive channel gating, and an intrinsically unstructured regula-
tory (R) domain that controls channel activity via PKA-mediated
phosphorylation (Figure 1A). CFTR synthesis has been esti-
mated to take 9–10 min in eukaryotic cells (Ward and Kopito,
1994), suggesting that significant folding occurs cotranslation-
ally. Like most polytopic membrane proteins, CFTR biogenesis
occurs at the ER, and requires coordinated folding of individual
domains in three distinct cellular compartments: the ER mem-
brane, the ER lumen, and the cytosol. This compartmentalization
takes place as the nascent chain emerges from the ribosome.
Subsequent assembly of TMDs and NBDs into the final folded
structure takes ∼30–120 min and is facilitated by a large cohort
of cytosolic and lumenal chaperones including Hsp70, Hsp40,
Hsp90, calnexin, and others (Amaral, 2004; Skach, 2006; Wang
et al., 2006). If CFTR fails to achieve its native fold, chaperones
such as Hsp70 also act to recruit E3 (and/or E4) ubiquitin-
ligases that ubiquitinate CFTR and target the mutant protein
for degradation by the 26S proteasome. Thus, CFTR folding
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FIGURE 1 | Cystic fibrosis transmembrane conductance regulator structural organization. (A) Schematic diagram of CFTR showing transmembrane
topology and domain organization. (B) A predicted human CFTR structure based on homology model from Sav1866.
is constantly monitored by cellular quality control machinery
throughout its biogenesis.
This review will focus on the current state of knowledge as to
how CFTR domains fold, how they interact, how mutations alter
this process, and how misfolded conformations are distinguished
from native structure by cellular chaperone machinery.
MULTISPANNING MEMBRANE PROTEIN BIOGENESIS AT
THE ER
To understand specialized aspects of CFTR biogenesis, it is helpful
to first consider general mechanisms. In eukaryotic cells, mem-
brane proteins are targeted to the ER during synthesis by the
cytosolic signal recognition particle (SRP; Walter and Blobel,
1981), which brings the ribosome nascent chain complex (RNC)
to the Sec61 translocon (Figure 2A). As the RNC docks onto the
translocon, the insertion of the signal sequence into Sec61α opens
the protein conducting channel (PCC) and establishes a contin-
uous aqueous pathway from the ribosome exit tunnel into the
ER lumen (Figure 2; Crowley et al., 1993, 1994). Extracellular
peptide loops generally pass through the PCC cotranslationally
until synthesis of a hydrophobic TM segment (i.e., stop trans-
fer sequence) terminates nascent chain translocation (Haigh and
Johnson, 2002; Woolhead et al., 2004; Alder et al., 2005) and relaxes
the ribosome translocon junction to allow the downstream pep-
tide region access to the cytosol (Liao et al., 1997). TM segments
also move laterally out of the translocon as they integrate into
the lipid bilayer. In some cases, integration occurs via a pas-
sive thermodynamic partitioning (Martoglio et al., 1995; Heinrich
et al., 2000), whereas in others, it appears to be mechanistically
controlled by the ribosome translocon complex (RTC; Do et al.,
1996; Pitonzo et al., 2009). Indeed, TMs may be released from
the translocon individually, in pairs, or even groups depending
on specific properties and folding requirements of the substrate
(Meacock et al., 2002; McCormick et al., 2003; Sadlish et al.,
2005). Crystal structures of the Sec61αβγ homolog from M. jan-
naschii (SecYEβ) have suggested that TMs exit the translocon via
a lateral cleft between Sec61α TMs2-3 and TMs7-8 along one
side of the PCC (Van den Berg et al., 2004). Functional mam-
malian translocons also contain additional translocon-associated
proteins including the translocation-associated membrane protein
(TRAM), translocon-associated membrane protein (TRAP) com-
plex, signal peptidase complex, oligosaccharyltransferase (OST),
and others that modulate translocation, integration, and early pro-
cessing events (Schröder et al., 1999; Wang and Dobberstein, 1999;
Shibatani et al., 2005). Thus, the Sec61αβγ PCC functions as part
of a large integrated molecular machine.
In the simplest model, polytopic protein topology could be
established by alternating TMs (encoding signal or stop transfer
activity) that sequentially open the translocon pore into the ER
lumen to initiate translocation and close the pore to terminate
translocation and direct peptide segments into the cytosol. Such a
mechanism would maintain ER integrity while essentially stitching
TM segments into the bilayer via coordinated structural changes
at the lumenal and the cytosolic faces of the RTC (Johnson, 2003;
Sadlish and Skach, 2004; Pitonzo and Skach, 2006; Skach, 2009).
CFTR FOLDING
CFTR TM INSERTION AND TMD FORMATION
Homology models predict that CFTR exhibits a complex domain
swap structure in which two six-spanning helical bundles contain-
ing TMs1-2, 9-12 and TMs7-8, 3-6 are twisted around a central
ion-conducting pore (Locher et al., 2002; Dawson and Locher,
2006; Aller et al., 2009). Helical extensions of the TMs form intra-
cellular loops (ICL1-4) that project nearly 40 Å into the cytosol
and form docking sites for NBD1 and NBD2 (Figure 1B). It is
currently believed that ATP binding and hydrolysis at the inter-
face between the two NBDs transmits an allosteric conformational
change along the ICLs to the TMDs that controls channel gating.
This elegant structure immediately raises several important ques-
tions when considered from a biosynthetic viewpoint. First, how
do CFTR TMs acquire their proper topology as they are oriented
and integrated into the ER membrane? Second, how do TMs inter-
act during TMD assembly? Third, where do domain swapping and
assembly occur in relation to the translocon, i.e., where do TMs1-2
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FIGURE 2 | Variations of polytopic protein topogenesis. (A) Simplest
cotranslational topogenesis model in which ER targeting begins as signal
recognition particle (SRP) recognizes an emerging signal sequence (TM),
binds its receptor (SR) at the ER membrane, and transfers the RNC to the
Sec61 translocon. TM topology is achieved through alternating signal and stop
transfer activities that sequentially open and close the translocon pore.
Careful orchestration of ribosome translocon junction ensures delivery of
soluble domains into either cytosol or ER lumen and integration of TMs into
the bilayer. (B) For CFTR, topology of TM1 and TM2 is established by two
alternate pathways in which translocation is initiated by either TM1 (left) or
TM2 (right). Most CFTR nascent chains utilized a posttranslational mechanism
in which TM2 insertion drags TM1 into the translocon. (C) The short loop
between TM3 and TM4 (five residues) suggests that TM3 and TM4
simultaneously insert into the translocon as a helical hairpin. A similar
mechanism is also proposed for TM5-6, TM9-10, and TM11-12. (D) Stop
transfer activity of TM8 is weakened by Asp924 which results in transient
exposure of TM8 in the ER lumen before acquiring its final membrane
spanning topology.
and TMs3-6 transiently reside for the several minutes that it takes
to synthesize TMs7-8 and TMs9-12? An important consideration
is that CFTR TMs contain an unusually large number of poten-
tially ionizable residues (4 Arg, 2 Lys, 3 Glu, 1 Asp, and 1 His),
which likely establish a network of polar interactions within the
membrane. However, such residues would be predicted to delay
or destabilize integration of individual TMs in the bilayer (Hessa
et al., 2005). In addition, mutagenesis studies have revealed that
TMD assembly influences folding of cytosolic NBDs and visa versa
(Chen et al., 2004; Loo et al., 2008), such that domain folding and
domain–domain assembly exhibit a high degree of cooperativity.
One of the first identifiable features of CFTR folding involves
the orientation and integration of TMs into the ER membrane.
Early work from our group established that ER targeting occurs
as TM1 and TM2 emerge from the ribosome, bind SRP (Carlson
et al., 2005), and engage the Sec61 translocon via a novel mech-
anism that involves two alternative folding pathways (Lu et al.,
1998). Notably, TM1 lacks efficient signal anchor activity due to
the presence of two ionizable residues, Glu92 and Lys95, within its
membrane spanning region. As a result, TM1 initiates translo-
cation for only ∼25% of nascent CFTR polypeptides. For the
remaining 75% of chains, topology of the TM1-2 loop is estab-
lished by type I signal anchor activity of TM2. In this case, the
energy of TM2 insertion into the translocon, essentially “drags”
the first extracellular loop (ECL1) into the ER lumen, thereby
establishing the type II topology of TM1 (Figure 2B). While the
final outcome of the two pathways is identical, the latter differs
from the simple cotranslational model because TM1 acquires its
topology after TM2. Such a mechanism suggests that both TMs are
accommodated simultaneously either within or closely adjacent to
the translocon channel.
An important implication of this topogenesis mechanism is
highlighted by two CF-causing mutations, G85E and G91R, each
of which introduces an additional ionizable residue into TM1.
Both mutants completely block TM1 signal anchor activity but do
not affect TMD1 topology because TM1 can still be inserted into
the membrane by TM2 (Xiong et al., 1997). Despite achieving cor-
rect topology, however, G85E and G91R still disrupt CFTR folding
and trafficking (Xiong et al., 1997; Patrick et al., 2011). Analysis
of TM1-2 topogenesis gave rise to the early prediction that dis-
ease related mutations in different regions of CFTR might disrupt
folding via a common mechanism, namely by preventing higher
order tertiary domain–domain interactions (Xiong et al., 1997;
Skach, 2000). In the case of TM1, we proposed that insertion of
an additional polar residue disrupted the arrangement of helical
bundles and subsequent interactions between helical extensions
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and cytosolic NBDs (Xiong et al., 1997; Skach, 2000). This finding
led to the early proposal that normal CFTR folding requires pre-
cise formation of domain–domain contacts, similar to a molecular
jig-saw puzzle, which has recently been shown by several groups to
be a major defect in the ∆F508 mutation as well (Serohijos et al.,
2008; Mendoza et al., 2012; Rabeh et al., 2012).
TM3 also encodes an inefficient signal sequence that cooper-
ates with TM4 to translocate the intervening extracellular loop,
ECL2. Because ECL2 contains only five residues it is likely that
TM3 and TM4 insert simultaneously into the translocon pore as a
helical hairpin (Figure 2C). Similarly, TM5 and TM6, which func-
tion as signal anchor and stop transfer sequences, are separated
by only a single charged lysine residue, indicating that their topol-
ogy is also established together as ECL3 is translocated into the
ER lumen. This feature of coincident translocation by TM helical
hairpins is a common feature of native polytopic proteins (Sadlish
et al., 2005) and suggests that two closely spaced TMs could be
considered as a single functional topogenic determinant. How-
ever, few studies have investigated the mechanism by which such
determinants interact with the translocon to establish topology.
From these results, we propose a general, although admittedly
incomplete model in which TM1-2 topology is acquired through
the combined actions of weak type II SA (TM1) and strong type
I SA (TM2) activities. Subsequently, TM3-4 and TM5-6 insert
into Sec61 as helical hairpins to translocate short ECL2 and ECL3
loops. An interesting and currently unresolved question is whether
TMs or TM pairs partition freely into the bilayer from the small
Sec61αβγ pore, if they remain associated with Sec61 and/or other
translocon proteins during subsequent helical packing. This ques-
tion is particularly relevant in light of the mature domain swap
structure where TM1-2 ultimately bundles with TM9-12 and
TM3-6 with TM7-8. Given the prevalence of ionizable residues in
TMs1, 2, 3, and 6, final assembly likely requires precise alignment
of TMs prior to complete integration into the lipid bilayer.
When TM6 terminates translocation NBD1 cotranslationally
passes beneath the base of the ribosome into the cytosol. Several
features of CFTR suggest that during this process, the ribosome
transiently disengages from Sec61 to allow folding of the cytosolic
domains. CFTR TMD1 helices are predicted to extend ∼40–50 Å
from the membrane, and these extensions appear to provide a
preliminary docking site for NBD1 prior to synthesis of TMD2
(Xiong et al., 1997; Kleizen et al., 2005; Du and Lukacs, 2009). The
TMD extension plus bound NBD1 would therefore extend nearly
80 Å from the membrane surface, requiring that this region must
move away from the ribosome to avoid a major steric clash. It is
unknown whether a new translocon is recruited for TMD2 topo-
genesis, or whether preliminary assembly of the N-terminal half of
CFTR occurs within or adjacent to the translocon. Precisely where
these early folding events might take place and the factors involved
remain important as yet unanswered questions.
NOVEL MECHANISMS OF CFTR TMD2 TOPOGENESIS AND FOLDING
After completion of R-domain synthesis, TMD2 topology is estab-
lished in a cotranslational manner by alternating signal (TM7, 9,
and 11) and stop transfer (TM8, 10, and 12) sequences. As TM7
emerges from the ribosome, it efficiently directs membrane target-
ing and ECL4 translocation. TM8, which is separated from TM7
by ∼31 residues, terminates translocation, and redirects ICL3 in
the cytosol as expected. Interestingly, TM8 functions as an effi-
cient stop transfer only when it is normally paired with TM7, but
not in a heterologous context (Carveth et al., 2002; Enquist et al.,
2009). This suggests that TM7 either influences TM8 stop trans-
fer activity inside the translocon or alternatively, that TM7 affects
recognition of TM8 within the ribosome exit tunnel. To date, this
type of cooperativity appears unique to CFTR, although few pro-
teins have been studied at this level of detail. The remaining TM
pairs, TM9-10 and TM11-12, each encode signal anchor and stop
transfer sequences with short extracellular loops, and it is likely
that they insert into the translocon as helical hairpins much like
TM3-4 and TM5-6 (Carveth et al., 2002).
TMD2 exhibits several additional unusual folding behaviors. It
is well known that N-linked glycosylation sites must be at least 12–
14 residues from the lipid bilayer to be accessible to OST (Popov
et al., 1997; Nilsson and von Heijne, 2000). The CF mutation
T908N, however, creates a glycosylation site that is recognized by
OST even though it is only four-residues from the predicted N-
terminus of TM8. Given that the precise boundaries of CFTR TMs
are not yet known, one possible explanation for these findings is
that residues within TM8 that actually span the membrane bilayer
may differ from current predictions. Alternatively, if TM8 mem-
brane boundaries are accurately predicted by homology models,
then this finding suggests that TM8 transiently extends into the ER
lumen during CFTR synthesis and is then repositioned within the
membrane during subsequent folding and helical packing (Ham-
merle et al., 2000; Carveth et al., 2002; Figure 2D). Such behavior
could be due to either altered interactions with translocon compo-
nents that fail to recognize TM8 during synthesis, altered timing
of TM8 helix formation, or both. Interestingly, removal of an
aspartate residue from TM8 (D924V) prevents transient lumenal
exposure and at the same time confers independent stop transfer
activity. Although the original observation that TM8 might tran-
siently sample the lumenal environment was unexpected, there
is growing appreciation that other weakly hydrophobic TMs in
polytopic proteins do indeed undergo repositioning within the
membrane, either through interactions with neighboring TMs
during tertiary folding, or due to differences in membrane thick-
ness and/or composition that occur at various locations along the
secretory pathway (Meindl-Beinker et al., 2006; Hessa et al., 2007;
Skach, 2009; Nörholm et al., 2011).
Cystic fibrosis transmembrane conductance regulator also
exhibits a distinct mechanism of membrane integration. The first
clue came from the observation that after synthesis is completed,
CFTR remains transiently bound to a large protein complex with
properties similar to the RTC (Oberdorf et al., 2005). Release from
this complex into the bilayer requires both cytosol and energy.
In vitro photocrosslinking experiments further demonstrated that
TM8 can maintain stable interactions with Sec61α after cleav-
age of peptidyl tRNA bond, and that release from the translocon
also requires ATP (Pitonzo et al., 2009). Surprisingly, Asp924,
which influences TM8 stop transfer activity, is also responsible
for retaining TM8 within Sec61, suggesting that polar interactions
can rigidly hold a TM within the translocon structure (Pitonzo
et al., 2009). These results demonstrate that the translocon has
the capacity to regulate the timing of TM integration via specific
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protein–protein interactions and thereby potentially facilitate early
steps of TMD assembly (Do et al., 1996; Liao et al., 1997; Skach,
2009).
In summary, CFTR TMD biogenesis utilizes multiple mech-
anisms that deviate from a cotranslational topogenesis model
including: alternate co- and post-translational translocation path-
ways (TM1-2), coincident insertion of helical hairpins (TM3-
4, TM5-6, TM9-10, and TM11-12), cooperativity for topogenic
determinant function (TM7-8), and regulated integration into
the ER membrane. Reasons underlying these distinct translo-
cation mechanisms are only beginning to be understood, but
evidence suggests that different folding pathways have functional
implications. For example, replacement of ionizable residues in
TM1 (E92A and K95A) converts TM1 to a strong signal anchor
sequence, thus favoring cotranslational topogenesis, but disrupts
CFTR function (Lu et al., 1998; Patrick et al., 2011). Similarly,
the D924V mutation converts TM8 to a strong strop transfer
sequence and facilitates cotranslational membrane integration,
but decreases CFTR chloride conductance (our observations).
These results are mirrored in the mammalian aquaporin family
and suggest that by facilitating different topogenesis mechanisms,
eukaryotic translocon machinery has allowed TM segments to
accommodate key functional residues that would otherwise dis-
rupt cotranslational membrane insertion (Skach, 2009). An obvi-
ous but profound implication is that folding and function are
closely intertwined such that structural elements needed for higher
order folding ultimately dictate which topogenesis mechanisms
prevail.
CFTR CYTOPLASMIC DOMAIN FOLDING AND THE DEFECT OF∆F508
It is now evident that correct folding of individual CFTR domains
is required for proper domain assembly, and that proper domain
assembly reciprocally influences domain folding (Qu and Thomas,
1996; Younger et al., 2006; Loo et al., 2008; Du and Lukacs, 2009;
Thibodeau et al., 2010). Among these processes, NBD1 folding
and mechanism(s) by which folding is disrupted by ∆F508 have
received intense attention. NBD1 is composed of three subdo-
mains: an N-terminal subdomain that contains the ATP binding
site (Khushoo et al., 2011), an α-helical subdomain containing
Phe508, and a central α/β core analogous to the F1-type ATPase
containing a six-stranded, largely parallel β-sheet (Figure 3).
NBD1 also contains the canonical LSGGQ signature motif (residue
548–552), a unique unstructured regulatory insertion (residues
404–436), a structurally diverse region (residues 526–547), and a
C-terminal regulatory extension (RE; Figure 3A). Given its pro-
found effect on CFTR folding, it was initially surprising that the
∆F508 mutation has little effect on NBD1 crystal structure (Lewis
et al., 2004, 2005). However, recent work has revealed that ∆F508
significantly disrupts both kinetic and thermodynamic stability of
NBD1 as well as increasing local backbone dynamics at residues
507–511 (Hoelen et al., 2010; Lewis et al., 2010; Wang et al., 2010;
Rabeh et al., 2012). Moreover, the specific folding defect induced
by ∆F508 appears to reside at least in part within the α-helical
subdomain (Hoelen et al., 2010; Wang et al., 2010) as well as C-
terminal β-strands, S9 and S10 (Hudson et al., 2012). ∆F508 also
eliminates a hydrophobic contact between NBD1 and TMD2 that
is required for trafficking and channel gating (Serohijos et al.,
2008).
Mutations that increase NBD1 solubility and/or thermody-
namic stability (I539T, G550E, R553Q, and others; Teem et al.,
1993; DeCarvalho et al., 2002; Roxo-Rosa et al., 2006; Pissarra
et al., 2008; Hoelen et al., 2010) and/or decrease backbone flexi-
bility (Aleksandrov et al., 2012) can enhance both NBD1 folding
yield in cells and trafficking efficiency of full length WT as well
as ∆F508 CFTR (Figure 3B). Thus NBD1 folding per se, is a
liming step in both WT and ∆F508 CFTR biogenesis. Muta-
tions within ICL4 or NBD1 that restore NBD1–TMD2 interaction
also improve ER export and chloride channel function (Sero-
hijos et al., 2008; He et al., 2010; Loo et al., 2010; Thibodeau
et al., 2010; Aleksandrov et al., 2012). However, correction of both
the NBD1–TMD2 interface and NBD1 thermodynamic stability
are required to restore ∆F508 processing to near wild-type lev-
els (Mendoza et al., 2012; Rabeh et al., 2012). A major goal in
CF, therefore, is to identify small molecules that act at both of
these folding steps and thereby increase channel function in CF
patients.
FIGURE 3 | (A) Crystal structure of NBD1 showing subdomain organization and location of key structural elements (2BBO). (B) Slightly different view of (A),
showing location of suppressor mutations (1XMI).
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How then does NBD1 fold in cells, and which limiting steps
might provide a target for small molecule correction? NBD1 fold-
ing begins cotranslationally after TM6 terminates translocation,
and the elongating nascent chain moves into the cytosol through
the relaxed ribosome translocon junction (Carveth et al., 2002). It
is estimated to take roughly 1 min to synthesize NBD1 in eukary-
otic cells, and significant folding (as well as mis-folding of ∆F508)
occurs during this time (Kleizen et al., 2005; Hoelen et al., 2010).
However, understanding NBD1 cotranslational folding has been
technically challenging because of the complex biological folding
environment. For example, cotranslational folding is influenced by
the rate and vectorial nature of translation (Fedorov and Baldwin,
1997; Siller et al., 2010), the ribosome, and geometry of the ribo-
some exit tunnel (Woolhead et al., 2004; Lu and Deutsch, 2005;
Ziv et al., 2005; Kaiser et al., 2011), molecular crowding (Ellis,
2001), and interaction with several cellular chaperone networks
(Frydman, 2001; Ellis, 2007; Hartl and Hayer-Hartl, 2009).
One promising method to define folding transitions as the
nascent chain emerges from the ribosome is to measure fluores-
cence energy transfer (FRET) between Donor and Acceptor probes
that are cotranslationally incorporated at distant sites in primary
sequence but which become proximal to one another as the pro-
tein folds. Because FRET efficiency is highly sensitive to changes
in distance on a scale of ∼10–80 Å, changes in FRET that occur
at increasing chain lengths provide a sensitive readout for nascent
chain compaction and folding. Using this approach, Khushoo et al.
(2011) showed that NBD1 folding begins cotranslationally and
proceeds via discrete steps as individual subdomains emerge from
the ribosome. The first step involves abrupt compaction of the
N-terminal ATP binding subdomain (residues 389–500), which
occurs on a time scale similar to or exceeding the predicted rate of
translation. Because NBD1 has a very high contact order charac-
terized by a large number of long-distance intrachain interactions,
it is likely that the N-terminal subdomain provides a template or
scaffold upon which the α-helical subdomain and α/β-core assem-
ble. Finally,∆F508 does not measurably influence N-terminal sub-
domain folding, indicating that the ∆F508 defect occurs during
later folding of α-helical and/or α/β-core subdomains.
CFTR DOMAIN–DOMAIN ASSEMBLY
Based on the time required for CFTR to exit the ER, CFTR domain
assembly takes ∼30–120 min. This suggests a hierarchical process
in which domain folding begins cotranslationally and is followed
by posttranslational formation of domain–domain contacts (Ost-
edgaard et al., 1997; Du et al., 2005; Cui et al., 2007; Figure 4).
During this time CFTR undergoes at least two distinct folding
events that require ATP. The first involves release of full length
CFTR from a large biosynthetic complex that likely includes the
RTC and cellular chaperones, and appears to coincide with CFTR
integration (i.e., release) into the bilayer of the ER membrane
FIGURE 4 | Step-wise CFTR folding pathway. (A) CFTR folding begins
cotranslationally as individual domains are synthesized, and proceeds as
domains assemble into a mature tertiary structure. (B) The ∆F508 mutation
destabilizes NBD1 structure, interferes with the TMD1, TMD2, and NBD2
folding, and disturbs interactions between NBD1 and ICL4, compromising
domain–domain assembly.
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(Meacham et al., 1999; Oberdorf et al., 2005). Both WT and
∆F508 CFTR undergo this step with equal efficiency (Oberdorf
et al., 2005). As discussed above, delayed integration of TMDs
may reflect the time required to establish the complex contacts
within the domain swap structure. It is not known how ATP
hydrolysis facilitates membrane integration, however, as no known
translocon components hydrolyze ATP. The second maturation
step involves conversion of CFTR from an immature, incompletely
folded, ER-associated conformation (typically designated as Band
B) to a properly folded, mature conformation that is competent to
exit the ER and undergo Golgi processing into the Band C form
(Lukacs et al., 1994). Interestingly, trapping CFTR in the ER with
Brefeldin A results in accumulation of a stable, “mature” Band B
form that is able to exit the ER upon Brefeldin A washout, indicat-
ing that the key folding step is distinct from Golgi processing. This
folding transition also involves reorganization and/or release of
cytosolic chaperones (Yang et al., 1993; Meacham et al., 1999) and
results in a substantial change in CFTR structure as demonstrated
by limited proteolysis (Zhang et al., 1998). Importantly, the∆F508
mutation prevents this latter step.
While the precise details of CFTR maturation remain a mystery,
WT and∆F508 conformations differ in several important aspects.
First, the complement of bound chaperones changes significantly;
Hsp/c70 is released from WT CFTR prior to ER export,but remains
bound to∆F508 CFTR and may stimulate degradation (Yang et al.,
1993; Matsumura et al., 2011). Second, the biological stability (as
measured by half-life) of ∆F508 CFTR is more temperature sensi-
tive than fully folded WT CFTR both in the ER and at the plasma
membrane (Zhang et al., 1998). Structural differences between WT
and mutant proteins can therefore be readily distinguished both
by ER and peripheral quality control machinery (Okiyoneda et al.,
2010). Third, channel activity of ∆F508 CFTR is more thermo-
labile than WT and rapidly declines at physiological temperatures
(37˚C; Aleksandrov et al., 2010; Wang et al., 2011; Liu et al., 2012).
Fourth, ∆F508 CFTR following maximal stimulation by PKA is
less biologically stable than quiescent channels (Liu et al., 2012),
indicating that features of the ∆F508 defect are mechanistically
linked to conformational changes that take place during the gating
cycle. Finally,different mechanisms of∆F508 correction (e.g., low-
temperature rescue, suppressor mutations,or small molecules) can
be accomplished by a variety of structural changes that give rise to
channels with different physical properties.
In addition to directly destabilizing NBD1 and weakening the
interface between NBD1 and TMD2, limited proteolysis and cys-
teine crosslinking studies indicate that ∆F508 also causes confor-
mational abnormalities in TMD1, TMD2, and NBD2 and misas-
sembly of TMD1/TMD2 and NBD1/NBD2 interfaces (Du et al.,
2005; Cui et al., 2007; Loo et al., 2008; Rosser et al., 2008; Du and
Lukacs, 2009; He et al., 2010; Thibodeau et al., 2010). This high
degree of cooperativity in CFTR domain folding is further sup-
ported by CF-related mutations in TMD1 and TMD2 that also
reciprocally affect the conformation of other domains (Du and
Lukacs, 2009).
THE ROLE OF CHAPERONES IN CFTR FOLDING
Because CFTR folding takes place in three different compartments,
the ER lumen, the ER membrane, and the cytosol, CFTR interacts
with several large cellular chaperone and co-chaperone networks
(at least 31 components) at various stages of folding (Skach, 2006;
Wang et al., 2006). Major chaperone families include cytosolic
Hsp70, Hsp90, and their co-chaperones (Yang et al., 1993; Loo
et al., 1998; Meacham et al., 1999; Younger et al., 2004; Grove
et al., 2011), as well as ER lumenal lectins calnexin and possibly
calreticulin (Pind et al., 1994; Harada et al., 2006).
Cytosolic chaperone interactions begin cotranslationally dur-
ing synthesis as Hsp/c70 binds and presumably shields extended
hydrophobic regions of the nascent chain to prevent aggregation
(Yang et al., 1993; Meacham et al., 1999; Oberdorf et al., 2005;
Kampinga and Craig, 2010). Hsp/c70 binds substrate in the ATP-
bound state, and binding is stabilized by ATP hydrolysis, which is
stimulated by DnaJ (Hsp40) cofactors. Substrate is released upon
nucleotide exchange, which can be either spontaneous, or stim-
ulated by nucleotide exchange factors (NEFs) such as Bag-1 and
HspBP1. While details of Hsp/c70-CFTR interactions are far from
complete, peptide binding studies have identified potential bind-
ing sites in NBD1, and have shown that Hsc70 decreases ∆F508
NBD1 aggregation in vitro possibly by reducing off-pathway fold-
ing events (Strickland et al., 1997; Figure 5). In cells, both Hsc70
and Hdj-2 interact with CFTR after the NBD1 synthesis but are
released in the presence of the R-domain (Meacham et al., 1999).
In addition, Hsp70 and Hdj-1 coexpression stabilizes WT CFTR
in vivo (Farinha et al., 2002), pointing out the critical role of
Hsp70 in CFTR NBD1 folding in the cytosol. Later stages of
TMD2 folding and TMD1 and TMD2 assembly appear to require
calnexin (Rosser et al., 2008) which likely binds TMD2 via N-
linked glycans attached to ECL4. This interaction may stabilize
TMD2 and/or assist in orienting TMs during domain swapping.
Taken together, these findings suggest that CFTR utilizes a carefully
orchestrated complement of chaperones at numerous sequential
and interdependent folding steps (Figure 5).
Paradoxically, chaperones that facilitate CFTR folding also play
a direct role in degradation. The best understood example is
Hsp70, which resides squarely at the intersection of folding and
quality control. Pro-folding activities of Hsp/c70 are mediated
through its N-terminal ATPase domain, which controls affinity
of the central peptide binding cleft. The C-terminus of Hsc70,
however, contains a tetratricopeptide binding motif that interacts
with at least one E3 ubiquitin ligase, CHIP, that functions in con-
cert with the E2 ubiquitin conjugating enzyme, UbcH5 (Meacham
et al., 2001; Younger et al., 2004). While other E3 ligases are also
implicated in CFTR ubiquitination (e.g., Nedd4-2, RMA1, and
gp78; Younger et al., 2006; Morito et al., 2008; Caohuy et al., 2009;
Grove et al., 2011), Hsc70-CHIP seems to play a major role in
recognizing cytosolic structural perturbations caused by ∆F508
(Meacham et al., 2001; Younger et al., 2004).
A non-trivial question therefore is how Hsp/c70 carries out two
diametrically opposed actions, on the one hand protecting pro-
teins from aggregation and facilitating folding, while on the other
identifying terminally misfolded proteins and targeting them for
degradation. An important clue was recently provided by Mat-
sumura et al. (2011) who used a C-terminal fragment of Bag-1 to
stimulate Hsc70 nucleotide exchange (Höhfeld and Jentsch, 1997;
Takayama et al., 1997). Addition of cBag during CFTR translation
slightly increased degradation, consistent with predictions that
www.frontiersin.org December 2012 | Volume 3 | Article 201 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kim and Skach CFTR folding in the cell
FIGURE 5 | Chaperones assist CFTR folding and target misfolded CFTR
for degradation. (A) As CFTR is synthesized, numerous chaperones and
co-chaperones (some depicted here) decorate the nascent polypeptide on
both lumenal and cytosolic sides of the ER membrane. Hsp70 and
co-chaperones interact with NBD1, followed by calnexin association with
TMD2. Hsp70-Hop interactions recruits Hsp90 complexes which likely aid
domain assembly in conjunction with calnexin. (B) Failure to achieve
productive folding at any step in the folding pathway is detected by persistent
binding of Hsp70, which serves to recruit E3 ligases (i.e., RMA1 and CHIP)
that ubiquitinate CFTR and target it to the 26S proteasome.
Hsp70-client interactions stimulate de novo folding (Meacham
et al., 1999; Younger et al., 2004; Grove et al., 2011), whereas similar
levels of cBag completely blocked CFTR degradation, consistent
with studies in yeast (Zhang et al., 2001) and mammalian cells
(Farinha et al., 2002). Kinetic analysis revealed that shortening the
time required for CFTR-Hsc70 dissociation from roughly 3 min
to less than 1 min resulted in a marked decrease in CFTR ubiqui-
tination and degradation. Thus, the timing of the Hsp70 binding
cycle, rather than binding per se, appears to be a critical decision
point in the degradation process.
Hsp/c70 also recruits Hsp90 complexes through the interme-
diate linker protein p60 (Hop; Frydman and Höhfeld, 1997). In
contrast to Hsp/c70, Hsp90 appears to primarily enhance CFTR
folding (Loo et al., 1998). During its binding cycle, conformational
shifts in Hsp90’s client binding interface likely induce structural
changes in substrate that mediate conversion from immature
to mature conformations. Hsp90-client binding is also regu-
lated by a variety of co-chaperones that include p23, cyclophilins
(i.e., FKBPs), and Aha1, each of which associates with CFTR in
cells (Wang et al., 2006; Hutt et al., 2012). While it is not yet
known precisely how Hsp90 affects CFTR folding, overexpres-
sion of the co-chaperone Aha1, which stimulates Hsp90 ATPase
activity and client release, decreases ∆F508 CFTR stability, and
Aha1 knockdown enhances ∆F508 processing. Thus, stabiliza-
tion of CFTR Hsp90 binding increases the dwell time of CFTR
in the Hsp90 complex, which may overcome a kinetic bock in
CFTR folding (Qu et al., 1997; Skach, 2006; Koulov et al., 2010).
A recent study has also shown that an additional Hsp90 co-
chaperone, a peptidylprolyl isomerase, FKBP8, interacts with and
stabilizes both WT and ∆F508 CFTR in the ER via a mecha-
nism that requires prolyl-isomerase activity (Hutt et al., 2012).
Thus the Hsp90 axis is a potentially attractive target for CFTR
correction.
SUMMARY
In summary, research in the past decade has revealed much
about how CFTR folds and misfolds in cells. Membrane inser-
tion and tertiary folding of cytosolic domains begin cotransla-
tionally during CFTR synthesis, whereas posttranslational fold-
ing involves assembly of TM helical bundles that provide crit-
ical domain–domain contacts needed to form a physiologically
stable structure. While the details of this process require fur-
ther refinement at the molecular level, the model that emerges
from these studies provides a useful framework to understand
the key folding defect(s) caused by ∆F508 in the majority of
CF patients. Within NBD1 itself, removal of Phe508 decreases
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folding efficiency and renders the domain susceptible to unfolding,
denaturation, and aggregation at physiologic temperatures, pos-
sibly as a direct result of destabilizing the α-helical subdomain.
Absence of Phe508 also disrupts the interaction between NBD1
and ICL4 (within TMD2), which distorts TMD structure and
interferes with channel gating. Defects in NBD1 and the NBD1–
ICL4 interface are both recognized by quality control machin-
ery, and correction of both is necessary and sufficient to restore
trafficking and function to near WT levels. Importantly, partial
correction of ∆F508 CFTR folding can be achieved by a variety
of means: cis-acting suppressor mutations, manipulation of the
proteostatic network, or small molecule correctors. Moreover,
combinations of these maneuvers are now able to achieve near
WT levels of surface expression and function. Thus, it is increas-
ingly attractive to target the next generation of CFTR small
molecule correctors to specific defects that will optimize syn-
ergy in correction mechanisms. While the most precise targets
reside within the CFTR molecule itself, i.e., NBD1 and the NBD1–
TMD2 interface, it is also possible that other clinically benefi-
cial targets will be developed in the years to come, which will
undoubtedly be driven by increasing resolution of the folding
problem.
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